BIOMAT Database Logo BIOMAT Database Logo

Development and pharmaceutical evaluation of the anticancer Anthrafuran/Cavitron complex, a prototypic parenteral drug formulation. 2017

Helen M Treshalina, and Vladimir I Romanenko, and Dmitry N Kaluzhny, and Michael I Treshalin, and Aleksey A Nikitin, and Alexander S Tikhomirov, and Andrey E Shchekotikhin
Federal State Budgetary Scientific Institution "N.N. Blokhin Russian Cancer Research Center" of the Ministry of Health of the Russian Federation, 24 Kashirskoye Shosse, Moscow 115478, Russia.

To improve the water solubility of the anticancer drug candidate LCTA-2034 (A1), we investigated the formation of complexes of this anthrax[2,3-b]furan congener with the solubilizing 2-hydroxypropyl derivative of β-cyclodextrin HP-βCD (Cavitron®). The interaction of A1 with HP-βCD resulted in the inclusion complex A1/HP-βCD in 1:1 stoichiometry. The A1/HP-βCD complex was used to develop a prototype of a lyophilised drug formulation with enhanced (>10-fold) aqueous solubility than A1 and a long-term stability. The use of HP-βCD decreased the acute toxicity of A1 by >30%. The A1/HP-βCD drug formulation as well as A1 in equal doses (5×30mg/kg) to increase the lifespan by up to 140% for mice with i.p. transplanted P388 leukaemia. Furthermore, the A1/HP-βCD formulation demonstrated a significant and reliable antitumor efficacy in a Р388/ADR drug resistant leukaemia and B16/F10 melanoma, proving a perspective of investigations of toxicology, biodistribution and pharmacokinetics.

UI MeSH Term Description Entries
D007928 Lethal Dose 50 The dose amount of poisonous or toxic substance or dose of ionizing radiation required to kill 50% of the tested population. LD50,Dose 50, Lethal
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008546 Melanoma, Experimental Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA. B16 Melanoma,Melanoma, B16,Melanoma, Cloudman S91,Melanoma, Harding-Passey,Experimental Melanoma,Experimental Melanomas,Harding Passey Melanoma,Melanomas, Experimental,B16 Melanomas,Cloudman S91 Melanoma,Harding-Passey Melanoma,Melanoma, Harding Passey,Melanomas, B16,S91 Melanoma, Cloudman
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008811 Mice, Inbred DBA An inbred strain of mouse. Specific substrains are used in a variety of areas of BIOMEDICAL RESEARCH such as DBA/1J, which is used as a model for RHEUMATOID ARTHRITIS. Mice, DBA,Mouse, DBA,Mouse, Inbred DBA,DBA Mice,DBA Mice, Inbred,DBA Mouse,DBA Mouse, Inbred,Inbred DBA Mice,Inbred DBA Mouse
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D005260 Female Females
D005663 Furans Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran. Tetrahydrofurans
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000073738 2-Hydroxypropyl-beta-cyclodextrin Derivative of beta-cyclodextrin that is used as an excipient for steroid drugs and as a lipid chelator. 2 Hydroxypropyl-beta-cyclodextrin,HP-beta-CD,HPbetaCD,Hydroxypropyl Betadex,Hydroxypropyl-beta-cyclodextrin,beta-Hydroxypropylcyclodextrin,2 Hydroxypropyl beta cyclodextrin,Betadex, Hydroxypropyl,Hydroxypropyl beta cyclodextrin,beta Hydroxypropylcyclodextrin

Related Publications

Helen M Treshalina, and Vladimir I Romanenko, and Dmitry N Kaluzhny, and Michael I Treshalin, and Aleksey A Nikitin, and Alexander S Tikhomirov, and Andrey E Shchekotikhin
Pharmaceutical development of a parenteral formulation of the investigational anticancer drug clanfenur.
January 1997, PDA journal of pharmaceutical science and technology,
Helen M Treshalina, and Vladimir I Romanenko, and Dmitry N Kaluzhny, and Michael I Treshalin, and Aleksey A Nikitin, and Alexander S Tikhomirov, and Andrey E Shchekotikhin
Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl.
January 2005, PDA journal of pharmaceutical science and technology,
Helen M Treshalina, and Vladimir I Romanenko, and Dmitry N Kaluzhny, and Michael I Treshalin, and Aleksey A Nikitin, and Alexander S Tikhomirov, and Andrey E Shchekotikhin
Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A.
November 2002, International journal of pharmaceutics,
Helen M Treshalina, and Vladimir I Romanenko, and Dmitry N Kaluzhny, and Michael I Treshalin, and Aleksey A Nikitin, and Alexander S Tikhomirov, and Andrey E Shchekotikhin
Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide F.
September 2001, Drug development and industrial pharmacy,
Helen M Treshalina, and Vladimir I Romanenko, and Dmitry N Kaluzhny, and Michael I Treshalin, and Aleksey A Nikitin, and Alexander S Tikhomirov, and Andrey E Shchekotikhin
Pharmaceutical development of a parenteral formulation of conivaptan hydrochloride.
January 2013, PDA journal of pharmaceutical science and technology,
Helen M Treshalina, and Vladimir I Romanenko, and Dmitry N Kaluzhny, and Michael I Treshalin, and Aleksey A Nikitin, and Alexander S Tikhomirov, and Andrey E Shchekotikhin
Pharmaceutical development of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum anticancer agent AP 5280.
October 2003, Drug development and industrial pharmacy,
Helen M Treshalina, and Vladimir I Romanenko, and Dmitry N Kaluzhny, and Michael I Treshalin, and Aleksey A Nikitin, and Alexander S Tikhomirov, and Andrey E Shchekotikhin
Development of a parenteral formulation of an investigational anticancer drug, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone.
January 1999, Pharmaceutical development and technology,
Helen M Treshalina, and Vladimir I Romanenko, and Dmitry N Kaluzhny, and Michael I Treshalin, and Aleksey A Nikitin, and Alexander S Tikhomirov, and Andrey E Shchekotikhin
Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine.
January 2000, PDA journal of pharmaceutical science and technology,
Helen M Treshalina, and Vladimir I Romanenko, and Dmitry N Kaluzhny, and Michael I Treshalin, and Aleksey A Nikitin, and Alexander S Tikhomirov, and Andrey E Shchekotikhin
Pharmaceutical development and manufacturing of a parenteral formulation of a novel antitumor agent, VNP40101M.
August 2001, AAPS PharmSciTech,
Helen M Treshalina, and Vladimir I Romanenko, and Dmitry N Kaluzhny, and Michael I Treshalin, and Aleksey A Nikitin, and Alexander S Tikhomirov, and Andrey E Shchekotikhin
Pharmaceutical development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent EO9.
January 1994, Cancer chemotherapy and pharmacology,
Copied contents to your clipboard!